Myrick F - Search Results

1

In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.

Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. Borroto-Esoda K, et al. Among authors: myrick f. Antivir Ther. 2006;11(3):377-84. Antivir Ther. 2006. PMID: 16759055

2

Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.

Feng JY, Myrick F, Selmi B, Deval J, Canard B, Borroto-Esoda K. Feng JY, et al. Among authors: myrick f. Antiviral Res. 2005 Jun;66(2-3):153-8. doi: 10.1016/j.antiviral.2005.03.001. Epub 2005 Apr 26. Antiviral Res. 2005. PMID: 15885814

3

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

Cihlar T, Ray AS, Boojamra CG, Zhang L, Hui H, Laflamme G, Vela JE, Grant D, Chen J, Myrick F, White KL, Gao Y, Lin KY, Douglas JL, Parkin NT, Carey A, Pakdaman R, Mackman RL. Cihlar T, et al. Among authors: myrick f. Antimicrob Agents Chemother. 2008 Feb;52(2):655-65. doi: 10.1128/AAC.01215-07. Epub 2007 Dec 3. Antimicrob Agents Chemother. 2008. PMID: 18056282 Free PMC article.

4

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, Borroto-Esoda K, Miller MD. Feng JY, et al. Among authors: myrick f. Retrovirology. 2009 May 13;6:44. doi: 10.1186/1742-4690-6-44. Retrovirology. 2009. PMID: 19439089 Free PMC article.

5

Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.

Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, Miller MD, Fridland A. Ray AS, et al. Among authors: myrick f. Antivir Ther. 2005;10(3):451-7. Antivir Ther. 2005. PMID: 15918336

6

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B. Feng JY, et al. Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107. doi: 10.1080/15257770500379157. Nucleosides Nucleotides Nucleic Acids. 2006. PMID: 16440988

7

In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.

Borroto-Esoda K, Myrick F, Feng J, Jeffrey J, Furman P. Borroto-Esoda K, et al. Among authors: myrick f. Antimicrob Agents Chemother. 2004 Nov;48(11):4387-94. doi: 10.1128/AAC.48.11.4387-4394.2004. Antimicrob Agents Chemother. 2004. PMID: 15504868 Free PMC article.

8

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD. Svarovskaia ES, et al. Among authors: myrick f. J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93. J Acquir Immune Defic Syndr. 2008. PMID: 18614922

9

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.

Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. Snow-Lampart A, et al. Among authors: myrick f. Hepatology. 2011 Mar;53(3):763-73. doi: 10.1002/hep.24078. Epub 2010 Dec 22. Hepatology. 2011. PMID: 21374657 Clinical Trial.

10

Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.

Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Harris JL, McCreedy B, Borroto-Esoda K. Mewshaw JP, et al. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):11-20. doi: 10.1097/00042560-200201010-00002. J Acquir Immune Defic Syndr. 2002. PMID: 11782585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters